Plomestane
| Clinical data | |
|---|---|
| ATC code | None |
| Identifiers | |
| |
| CAS Number | 77016-85-4 |
| PubChem (CID) | 9904788 |
| ChemSpider | 8080442 |
| Chemical and physical data | |
| Formula | C21H26O2 |
| Molar mass | 310.430 g/mol |
| 3D model (Jmol) | Interactive image |
| |
| |
Plomestane (INN, USAN) (former developmental code name MDL-18,962), also known as propargylestrenedione (PED), as well as 10-propargylestr-4-ene-3,17-dione, is a steroidal, irreversible aromatase inhibitor which was under development by Marion Merrell Dow/Hoechst Marion Russell (now Hoechst AG) as an antineoplastic agent for the treatment of breast cancer.[1][2][3][4][5] It was found to be effective in preclinical studies and was also found to produce few adverse effects in human clinical trials, significantly reducing estrogen levels with a single administration.[5] However, development of the drug for clinical use was halted due to "technical issues" and it was never marketed.[6]
Plomestane has weak androgenic properties.[5]
See also
References
- ↑ F.. Macdonald (1997). Dictionary of Pharmacological Agents. CRC Press. p. 1635. ISBN 978-0-412-46630-4. Retrieved 19 May 2012.
- ↑ Dr. Ian Morton; Ian K. M. Morton; Judith M. Hall; Dr. Judith Hall (1999). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer. p. 227. ISBN 978-0-7514-0499-9. Retrieved 20 May 2012. Cite uses deprecated parameter
|coauthors=(help) - ↑ Bentham Science Publishers (June 1995). Current Pharmaceutical Design. Bentham Science Publishers. p. 45. Retrieved 20 May 2012.
- ↑ Richard B. Kreider; Brian C. Leutholtz; Frank I. Katch; Victor L. Katch (2009). Exercise and Sport Nutrition. Exercise & Sport Nutrition. p. 350. ISBN 978-0-9742965-6-2. Retrieved 20 May 2012. Cite uses deprecated parameter
|coauthors=(help) - 1 2 3 Kelloff GJ, Lubet RA, Lieberman R, et al. (January 1998). "Aromatase inhibitors as potential cancer chemopreventives". Cancer Epidemiology, Biomarkers & Prevention. 7 (1): 65–78. PMID 9456245.
- ↑ Carmen Avendaño; J. Carlos Menéndez (4 June 2008). Medicinal Chemistry of Anticancer Drugs. Elsevier. p. 69. ISBN 978-0-444-52824-7. Retrieved 20 May 2012.
This article is issued from Wikipedia - version of the 12/4/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.